[140 Pages Report] The global fertility test market is expected to reach 583.1 million by 2023 from USD 411.8 million in 2018, at a CAGR of 7.2%. Growth in the fertility test market can be attributed to factors, such as increasing first-time pregnancy age, launch of advanced, easy-to-use fertility monitors with high accuracy, and increasing awareness about fertility testing.

The fertility test market is segment into 4 major segment: Product, Mode of purchase, application, end user and region.

By product, the OPK segment is expected to account for the largest share during the forecast period.

Based on product, the fertility test market is segmented into OPK, fertility monitors, and male fertility testing products. In 2018, the ovulation predictor kits segment is expected to account for the largest share of the fertility test market. The large share can be attributed to their low cost and high efficacy, high preference for these kits, and rising median age of first-time pregnancies in women.

By mode of purchase, the non-prescription/OTC-based segment is expected to account for the largest share during the forecast period.

Based on mode of purchase, the fertility test market is divided into two segments�prescription-based and non-prescription/OTC-based. In 2018, the non-prescription/OTC-based segment is expected to account for a larger share of the market. The large share can be attributed to factors such as the increasing patient preference for home- and remote monitoring, e-commerce availability, confidentiality, & accessibility of test results, and growing initiatives taken by leading market players to develop easy-to-use and accurate products.

By application, the female fertility testing segment is expected to account for the largest share during the forecast period.

On the basis of application, the fertility test market is segmented into female fertility testing and male fertility testing. In 2018, the female fertility testing segment is expected to account for a larger share of the fertility test market. The large share can be attributed to factors such as decreasing female fertility rates, availability of a wide range of fertility testing options, and high cost of IVF procedures.

By end user, the home care settings segment is expected to account for the largest share during the forecast period.

The fertility test market, by end user, is segmented into home care settings and hospitals, fertility clinics, and others. In 2018, the home care settings segment is expected to account for the largest share of the fertility test market. The large share can be attributed to the decline of fertility rates in women and men, increasing need for continuous monitoring of health conditions, and growing preference for home and remote monitoring.

Regional Analysis: Fertility Test Market, by End User

The North America region is expected to account for the largest share during the forecast period.

The report covers the fertility test market across four key geographies, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to dominate the global fertility test market in 2018. The decline in fertility rate, rising first-time pregnancy age, and high prevalence of PCOS (polycystic ovary syndrome) among North American women are few of the major factors contributing the large share of this regional segment. Additionally, factors such as the growing use of fertility monitoring devices for contraception, rising awareness about the benefits of ovulation monitors through social media, marketing campaigns, and e-commerce sites are increasing the adoption of fertility test in this region.

Market Dynamics

Growth in the fertility test market can be attributed to factors such as the increasing first-time pregnancy age in women, declining fertility rate among men and women, growing number of women suffering from disorders such as PCOS, emergence of advanced ovulation monitors, and increased awareness of fertility testing in both developed as well as developing countries. On the other hand, the unproven accuracy of urine-based ovulation monitors in women suffering from PCOS and the lesser precision to confirm ovulation using ovulation predictions kits are the factors that are expected to restrain market growth to a certain extent in the coming years.

Key Market Players

The leading players in the fertility test market included SPD Swiss Precision Diagnostics GmbH (Swiss Precision Diagnostics) (Switzerland), and Church & Dwight Co., Inc. (Church & Dwight) (U.S.),. Other players in this market include Valley Electronics GmbH (Valley Electronics) (Germany) , Geratherm Medical AG (Geratherm) (Germany), Prestige Brands Holdings, Inc. (Prestige Brands Holdings) (U.S.), Hilin Life Products, Inc. (Hilin Life) (US), Fairhaven Health, LLC (Fairhaven Health) (U.S.), Fertility Focus Limited (Fertility Focus) (UK), bioZhena Corporation (bioZhena) (US), TaiDoc Technology Corporation (TaiDoc) (Taiwan), UEBE Medical GmbH (UEBE Medical) (Germany), AdvaCare Pharma (US), Ava (Switzerland), Babystart Ltd. (Babystart) (UK), and Sensiia (UK).

Swiss Precision Diagnostics (Switzerland) held the leading position in the global fertility testing devices market. The company is one of the leading manufacturers and suppliers of fertility/ovulation tests for women. Clearblue is the flagship product of the company and has a very strong brand presence in countries such as the US, the UK, and Europe. Along with this, the company�s wide distribution network and innovative marketing strategies are the key factors contributing to its dominant share in the market. With the aim to maintain its dominant share in this highly competitive market, SPD focuses on product launches as its key growth strategy.

Recent Developments

In 2017, Swiss Precision Diagnostics (Switzerland) launched its Clearblue Connected Ovulation Test System

In 2017, NFI Consumer Healthcare (US) a division of Gregory Pharmaceutical Holdings (US) completed the acquisition of e.p.t over-the-counter pregnancy test kit brand from Prestige Brands Holdings.

In 2017, Fairhaven Health (US), launched TempCue, a basal body temperature (BBT) thermometer.

In 2016, Fertility Focus (UK) launched OvuSense App.

Key Questions Addressed by the Report:

What are the growth opportunities related to the adoption of fertility test products across major regions in the future?

Emerging countries have immense opportunities for the growth and adoption of ovulation prediction kits. Will this scenario continue in the next five years?

Where will all the advancements in products offered by various companies take the industry in the mid- to long-term?

How will the increasing use of ovulation tracking mobile apps and fertility-tracking websites affect the growth of the market?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst